Navigation Links
Aeterna Zentaris: Perifosine Data Selected for Oral Presentation at Upcoming 12th World Congress on Gastrointestinal Cancer
Date:6/29/2010

QUEBEC CITY, June 29 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrine therapy, today announced that abstract O-0017, entitled, "Subset Analysis of 5-FU Refractory Patients from a Randomized Phase 2 Study of Perifosine + Capecitabine (P-CAP) vs. Placebo + Capecitabine (CAP) in Patients with 2nd or 3rd Line Metastatic CRC", has been selected for oral presentation at the upcoming 12th World Congress on Gastrointestinal Cancer, to be held in Barcelona, Spain, from June 30-July 2, 2010. The oral presentation will be made by Paulo Hoff, M.D., Professor of Medicine and Chairman of Medical Oncology at the University of Sao Paulo, Brazil and former lead investigator for the capecitabine (Xeloda(R)) Phase 3 approval study in metastatic colorectal cancer.

Of the 38 patients enrolled in the Phase 2 study, 27 patients were previously refractory to a 5-FU based regimen. A Phase 3 randomized double-blind trial comparing perifosine + capecitabine vs. placebo + capecitabine in 5-FU refractory patients with advanced refractory colorectal cancer (X-PECT trial), under Special Protocol Assessment (SPA) from the Food and Drug Administration (FDA), is currently open and enrolling patients at multiple centers throughout the U.S. This Phase 3 trial is sponsored by Keryx Biopharmaceuticals, Inc. ("Keryx") (Nasdaq: KERX), Aeterna Zentaris' licensee for perifosine in the United States, Canada and Mexico.

About Perifosine

Perifosine, a novel, potentially first-in-class, oral Akt inhib
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Aeterna Zentaris Announces Collaboration with Almac to Develop Therapy and Companion Diagnostic in Cancer
2. Aeterna Zentaris Receives US$12 Million on Closing of Registered Direct Offering
3. Aeterna Zentaris to Raise US$12 Million in Registered Direct Offering
4. Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency
5. Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results
6. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
7. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
8. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
9. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
10. AEterna Zentaris Announces Appointment of New Board Member
11. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 25, 2014 Lawrence Livermore scientists Charles ... Reuters list of " The World's Most Influential Scientific ... the 3,000 researchers who were identified by analyzing citation ... who published the highest-impact work (2002-2012 and 2012-2013). The ... combustion modeling . , "This recognition is a ...
(Date:7/25/2014)... Sinovac Biotech Ltd. (Nasdaq: SVA ), a leading ... today announced that it will release its unaudited financial results ... close on Thursday, August 14, 2014 EDT. The Company will ... Friday, August 15, 2014, at 8:00 a.m. EDT (Friday, August ... the Company,s financial results and provide an update on recent ...
(Date:7/24/2014)...  Now available is a stem cell therapy that ... , located in Guadalajara, Mexico , ... new health option: stem cell therapies for sports ... suffer from joint and muscle injuries due to professional ... rotator cuff, tennis elbow, and knee injuries. Throughout life ...
(Date:7/24/2014)... A research team led by group leader Yung-Eun ... technology to synthesize sulfur-doped and nitrogen-doped graphenes which ... secondary batteries and fuel cells. Yung-Eun Sung is ... Nanoparticle Research at Institute for Basic Science* (IBS) ... , This achievement has great significance with regards ...
Breaking Biology Technology:Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3
... December 2 NicOx S.A.,(NYSE Euronext Paris: ... agreement with,DSM for the commercial manufacture and ... pharmaceutical ingredient). Naproxcinod is NicOx, lead,investigational product ... Oxide-Donating (CINOD) class of,anti-inflammatory agents, which recently ...
... (Pink Sheets: CGCP), a leading developer of surgical products used ... announced the addition of veteran medical device executive and an ... of the Company,s Board of Directors, increasing the number of ... Mr. Cohen, 49, has over 25 years of executive ...
... SHANGHAI, China, Dec. 2 /PRNewswire-Asia/ -- WuXi PharmaTech ... pharmaceutical, biotechnology and medical device,research and development outsourcing ... today announced it will dedicate its Philadelphia facility ... cell therapy,services, and as of December 31, 2008, ...
Cached Biology Technology:NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 2NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 3NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 4Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors 2Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors 3WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services 2WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services 3WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services 4WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services 5
(Date:7/27/2014)... revealed that nicotine and cotinine, a metabolite of nicotine, ... carcinogen in smoke. , The carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone or NNK ... ultimately ends up in the tobacco smoke. Once inhaled, ... it is activated by a variety of enzymes called ... that nicotine can partially interfere with the activation of ...
(Date:7/27/2014)... strike that wiped them out if it had taken ... , A fresh study using up-to-date fossil records and ... new narrative of the prehistoric creatures, demise, some 66 ... few million years before a 10km-wide asteroid struck what ... included extensive volcanic activity, changing sea levels and varying ...
(Date:7/27/2014)... the largest prevalence studies to date, researchers from the ... for the hepatitis C virus (HCV). Findings published in ... Study of Liver Diseases, indicate that genotype 1 is ... infected of which one-third reside in East Asia. Genotype ... next most prevalent, followed by genotypes 2, 4, 6, ...
Breaking Biology News(10 mins):Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2Dinosaurs fell victim to perfect storm of events, study shows 2Hepatitis C virus genotype 1 is most prevalent worldwide 2
... How,s this for precision? Researchers with the University of ... knock single atoms off a silicon wafer without disturbing ... engineering professor Vince Donnelly and Demetre Economou, Hugh Roy ... same department, are supported in this project by an ...
... to share knowledge, projects and developments in ... creation of synergies and possible frameworks for ... and institutions that address this matter. ... and will be open untill November 11th., ...
... at the National Science Foundation (NSF)--working cooperatively with ... field science supported by the U.S. Antarctic Program, ... to the maximum extent possible, following the October ... a Presidential mandate to manage the U.S. Antarctic ...
Cached Biology News:Creating smaller, and more powerful, integrated circuits 2NSF, US Antarctic Program partners, working to restore Antarctic research season to the maximum extent possible 2NSF, US Antarctic Program partners, working to restore Antarctic research season to the maximum extent possible 3
... 384, compatible with hood ... handling system for 384-well ... accurately prepares large quantities ... The Wellpro also performs ...
MBS 384 well satellite block unit with height adjusting heated lid, 384 well block holds 1 x 0.04 ml 384 well plate...
... has been determined, the challenge is to ... audience of scientists, educators and students. Current ... over the Internet, either via online journals ... literature has the advantage of wide acceptance ...
... 45° Fixed Angle rotor for ... CL2, Centra CL3/CL3R, HN-SII or ... style rotor accepts 15 mL ... disposable conical tubes as well ...
Biology Products: